nodes	percent_of_prediction	percent_of_DWPC	metapath
Etravirine—CYP3A4—bone cancer	0.792	1	CbGaD
Etravirine—CYP2C9—Cisplatin—bone cancer	0.0152	0.275	CbGbCtD
Etravirine—ABCB1—Cisplatin—bone cancer	0.0148	0.267	CbGbCtD
Etravirine—Rilpivirine—NR1I2—bone cancer	0.0114	0.835	CrCbGaD
Etravirine—ABCB1—Doxorubicin—bone cancer	0.0099	0.179	CbGbCtD
Etravirine—ABCB1—Methotrexate—bone cancer	0.00959	0.173	CbGbCtD
Etravirine—CYP3A4—Doxorubicin—bone cancer	0.00593	0.107	CbGbCtD
Etravirine—ABCB4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00389	0.143	CbGpPWpGaD
Etravirine—ABCB4—Farnesoid X Receptor  Pathway—CYP3A4—bone cancer	0.00362	0.133	CbGpPWpGaD
Etravirine—ABCB4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00227	0.0837	CbGpPWpGaD
Etravirine—Rilpivirine—CYP3A4—bone cancer	0.00225	0.165	CrCbGaD
Etravirine—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000948	0.035	CbGpPWpGaD
Etravirine—ABCB1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000929	0.0343	CbGpPWpGaD
Etravirine—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00087	0.0321	CbGpPWpGaD
Etravirine—ABCB1—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.000869	0.0321	CbGpPWpGaD
Etravirine—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000864	0.0319	CbGpPWpGaD
Etravirine—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000826	0.0305	CbGpPWpGaD
Etravirine—Urethral disorder—Cisplatin—bone cancer	0.000603	0.00539	CcSEcCtD
Etravirine—Gynaecomastia—Methotrexate—bone cancer	0.000602	0.00537	CcSEcCtD
Etravirine—Inflammation—Doxorubicin—bone cancer	0.0006	0.00536	CcSEcCtD
Etravirine—Abnormal dreams—Doxorubicin—bone cancer	0.000576	0.00514	CcSEcCtD
Etravirine—Eye disorder—Cisplatin—bone cancer	0.000575	0.00514	CcSEcCtD
Etravirine—Cardiac disorder—Cisplatin—bone cancer	0.000571	0.0051	CcSEcCtD
Etravirine—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00057	0.021	CbGpPWpGaD
Etravirine—Diabetes mellitus—Methotrexate—bone cancer	0.000561	0.00501	CcSEcCtD
Etravirine—Immune system disorder—Cisplatin—bone cancer	0.000556	0.00497	CcSEcCtD
Etravirine—Mediastinal disorder—Cisplatin—bone cancer	0.000555	0.00495	CcSEcCtD
Etravirine—Hepatic failure—Methotrexate—bone cancer	0.000543	0.00485	CcSEcCtD
Etravirine—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000536	0.0198	CbGpPWpGaD
Etravirine—Malnutrition—Cisplatin—bone cancer	0.000536	0.00479	CcSEcCtD
Etravirine—Renal failure acute—Methotrexate—bone cancer	0.000529	0.00472	CcSEcCtD
Etravirine—Flatulence—Cisplatin—bone cancer	0.000528	0.00472	CcSEcCtD
Etravirine—Diabetes mellitus—Epirubicin—bone cancer	0.000525	0.00469	CcSEcCtD
Etravirine—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000509	0.0188	CbGpPWpGaD
Etravirine—Hepatic failure—Epirubicin—bone cancer	0.000508	0.00454	CcSEcCtD
Etravirine—Vision blurred—Cisplatin—bone cancer	0.000505	0.00451	CcSEcCtD
Etravirine—Tremor—Cisplatin—bone cancer	0.000502	0.00448	CcSEcCtD
Etravirine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.0005	0.0184	CbGpPWpGaD
Etravirine—Ill-defined disorder—Cisplatin—bone cancer	0.000497	0.00444	CcSEcCtD
Etravirine—Anaemia—Cisplatin—bone cancer	0.000495	0.00442	CcSEcCtD
Etravirine—Renal failure acute—Epirubicin—bone cancer	0.000495	0.00442	CcSEcCtD
Etravirine—Diabetes mellitus—Doxorubicin—bone cancer	0.000486	0.00434	CcSEcCtD
Etravirine—Malaise—Cisplatin—bone cancer	0.000483	0.00432	CcSEcCtD
Etravirine—Dermatitis bullous—Epirubicin—bone cancer	0.000478	0.00427	CcSEcCtD
Etravirine—Hepatic failure—Doxorubicin—bone cancer	0.00047	0.0042	CcSEcCtD
Etravirine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000467	0.0172	CbGpPWpGaD
Etravirine—Convulsion—Cisplatin—bone cancer	0.000464	0.00415	CcSEcCtD
Etravirine—Renal failure acute—Doxorubicin—bone cancer	0.000458	0.00409	CcSEcCtD
Etravirine—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000457	0.0169	CbGpPWpGaD
Etravirine—Anxiety—Cisplatin—bone cancer	0.000455	0.00406	CcSEcCtD
Etravirine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000453	0.00405	CcSEcCtD
Etravirine—Discomfort—Cisplatin—bone cancer	0.000451	0.00403	CcSEcCtD
Etravirine—Dermatitis bullous—Doxorubicin—bone cancer	0.000442	0.00395	CcSEcCtD
Etravirine—Breast disorder—Methotrexate—bone cancer	0.000441	0.00394	CcSEcCtD
Etravirine—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.00044	0.0162	CbGpPWpGaD
Etravirine—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.00044	0.00393	CcSEcCtD
Etravirine—Infection—Cisplatin—bone cancer	0.000434	0.00388	CcSEcCtD
Etravirine—Nervous system disorder—Cisplatin—bone cancer	0.000429	0.00383	CcSEcCtD
Etravirine—Thrombocytopenia—Cisplatin—bone cancer	0.000428	0.00382	CcSEcCtD
Etravirine—Skin disorder—Cisplatin—bone cancer	0.000425	0.00379	CcSEcCtD
Etravirine—Hyperhidrosis—Cisplatin—bone cancer	0.000423	0.00378	CcSEcCtD
Etravirine—Dry skin—Epirubicin—bone cancer	0.000419	0.00374	CcSEcCtD
Etravirine—Eosinophilia—Methotrexate—bone cancer	0.000418	0.00373	CcSEcCtD
Etravirine—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000417	0.0154	CbGpPWpGaD
Etravirine—Anorexia—Cisplatin—bone cancer	0.000417	0.00372	CcSEcCtD
Etravirine—Pancreatitis—Methotrexate—bone cancer	0.000414	0.0037	CcSEcCtD
Etravirine—Breast disorder—Epirubicin—bone cancer	0.000413	0.00369	CcSEcCtD
Etravirine—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.000411	0.00367	CcSEcCtD
Etravirine—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000408	0.0151	CbGpPWpGaD
Etravirine—Gastritis—Epirubicin—bone cancer	0.000404	0.00361	CcSEcCtD
Etravirine—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000401	0.0148	CbGpPWpGaD
Etravirine—Abdominal distension—Epirubicin—bone cancer	0.000398	0.00355	CcSEcCtD
Etravirine—Paraesthesia—Cisplatin—bone cancer	0.000393	0.00351	CcSEcCtD
Etravirine—Eosinophilia—Epirubicin—bone cancer	0.000391	0.00349	CcSEcCtD
Etravirine—Dry skin—Doxorubicin—bone cancer	0.000387	0.00346	CcSEcCtD
Etravirine—Pancreatitis—Epirubicin—bone cancer	0.000387	0.00346	CcSEcCtD
Etravirine—Angina pectoris—Epirubicin—bone cancer	0.000385	0.00344	CcSEcCtD
Etravirine—Breast disorder—Doxorubicin—bone cancer	0.000382	0.00341	CcSEcCtD
Etravirine—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.000381	0.0034	CcSEcCtD
Etravirine—Decreased appetite—Cisplatin—bone cancer	0.00038	0.0034	CcSEcCtD
Etravirine—Gastrointestinal disorder—Cisplatin—bone cancer	0.000378	0.00337	CcSEcCtD
Etravirine—Gastritis—Doxorubicin—bone cancer	0.000374	0.00334	CcSEcCtD
Etravirine—Pain—Cisplatin—bone cancer	0.000374	0.00334	CcSEcCtD
Etravirine—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000373	0.00333	CcSEcCtD
Etravirine—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000372	0.0137	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—NDUFA12—bone cancer	0.000372	0.0137	CbGpPWpGaD
Etravirine—Renal failure—Methotrexate—bone cancer	0.00037	0.0033	CcSEcCtD
Etravirine—Abdominal distension—Doxorubicin—bone cancer	0.000368	0.00329	CcSEcCtD
Etravirine—Stomatitis—Methotrexate—bone cancer	0.000367	0.00328	CcSEcCtD
Etravirine—Conjunctivitis—Methotrexate—bone cancer	0.000366	0.00327	CcSEcCtD
Etravirine—Eosinophilia—Doxorubicin—bone cancer	0.000362	0.00323	CcSEcCtD
Etravirine—Feeling abnormal—Cisplatin—bone cancer	0.00036	0.00322	CcSEcCtD
Etravirine—Pancreatitis—Doxorubicin—bone cancer	0.000358	0.0032	CcSEcCtD
Etravirine—Hyperglycaemia—Epirubicin—bone cancer	0.000356	0.00318	CcSEcCtD
Etravirine—Angina pectoris—Doxorubicin—bone cancer	0.000356	0.00318	CcSEcCtD
Etravirine—Hepatobiliary disease—Methotrexate—bone cancer	0.000356	0.00318	CcSEcCtD
Etravirine—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000349	0.00312	CcSEcCtD
Etravirine—Renal failure—Epirubicin—bone cancer	0.000346	0.00309	CcSEcCtD
Etravirine—Body temperature increased—Cisplatin—bone cancer	0.000346	0.00309	CcSEcCtD
Etravirine—Neuropathy peripheral—Epirubicin—bone cancer	0.000345	0.00308	CcSEcCtD
Etravirine—Stomatitis—Epirubicin—bone cancer	0.000343	0.00307	CcSEcCtD
Etravirine—Conjunctivitis—Epirubicin—bone cancer	0.000342	0.00306	CcSEcCtD
Etravirine—Hepatitis—Methotrexate—bone cancer	0.000338	0.00302	CcSEcCtD
Etravirine—Urinary tract disorder—Methotrexate—bone cancer	0.000334	0.00298	CcSEcCtD
Etravirine—Hepatobiliary disease—Epirubicin—bone cancer	0.000333	0.00297	CcSEcCtD
Etravirine—Urethral disorder—Methotrexate—bone cancer	0.000331	0.00296	CcSEcCtD
Etravirine—Hyperglycaemia—Doxorubicin—bone cancer	0.00033	0.00294	CcSEcCtD
Etravirine—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000323	0.00288	CcSEcCtD
Etravirine—Hypersensitivity—Cisplatin—bone cancer	0.000322	0.00288	CcSEcCtD
Etravirine—Renal failure—Doxorubicin—bone cancer	0.00032	0.00286	CcSEcCtD
Etravirine—Erythema multiforme—Methotrexate—bone cancer	0.000319	0.00285	CcSEcCtD
Etravirine—Neuropathy peripheral—Doxorubicin—bone cancer	0.000319	0.00285	CcSEcCtD
Etravirine—Stomatitis—Doxorubicin—bone cancer	0.000318	0.00284	CcSEcCtD
Etravirine—Conjunctivitis—Doxorubicin—bone cancer	0.000317	0.00283	CcSEcCtD
Etravirine—Hepatitis—Epirubicin—bone cancer	0.000316	0.00282	CcSEcCtD
Etravirine—Eye disorder—Methotrexate—bone cancer	0.000316	0.00282	CcSEcCtD
Etravirine—Hypoaesthesia—Epirubicin—bone cancer	0.000314	0.00281	CcSEcCtD
Etravirine—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000314	0.0116	CbGpPWpGaD
Etravirine—Asthenia—Cisplatin—bone cancer	0.000314	0.0028	CcSEcCtD
Etravirine—Cardiac disorder—Methotrexate—bone cancer	0.000313	0.0028	CcSEcCtD
Etravirine—Urinary tract disorder—Epirubicin—bone cancer	0.000312	0.00279	CcSEcCtD
Etravirine—Connective tissue disorder—Epirubicin—bone cancer	0.000311	0.00277	CcSEcCtD
Etravirine—Urethral disorder—Epirubicin—bone cancer	0.00031	0.00277	CcSEcCtD
Etravirine—ABCB4—Metabolism—NT5C3A—bone cancer	0.000308	0.0114	CbGpPWpGaD
Etravirine—Hepatobiliary disease—Doxorubicin—bone cancer	0.000308	0.00275	CcSEcCtD
Etravirine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000308	0.0114	CbGpPWpGaD
Etravirine—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000307	0.0113	CbGpPWpGaD
Etravirine—Angiopathy—Methotrexate—bone cancer	0.000306	0.00274	CcSEcCtD
Etravirine—Immune system disorder—Methotrexate—bone cancer	0.000305	0.00272	CcSEcCtD
Etravirine—Mediastinal disorder—Methotrexate—bone cancer	0.000304	0.00272	CcSEcCtD
Etravirine—Diarrhoea—Cisplatin—bone cancer	0.000299	0.00267	CcSEcCtD
Etravirine—Erythema multiforme—Epirubicin—bone cancer	0.000299	0.00267	CcSEcCtD
Etravirine—Mental disorder—Methotrexate—bone cancer	0.000296	0.00264	CcSEcCtD
Etravirine—Eye disorder—Epirubicin—bone cancer	0.000295	0.00264	CcSEcCtD
Etravirine—Malnutrition—Methotrexate—bone cancer	0.000294	0.00263	CcSEcCtD
Etravirine—Cardiac disorder—Epirubicin—bone cancer	0.000293	0.00262	CcSEcCtD
Etravirine—Hepatitis—Doxorubicin—bone cancer	0.000292	0.00261	CcSEcCtD
Etravirine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000292	0.0108	CbGpPWpGaD
Etravirine—Hypoaesthesia—Doxorubicin—bone cancer	0.000291	0.0026	CcSEcCtD
Etravirine—Urinary tract disorder—Doxorubicin—bone cancer	0.000289	0.00258	CcSEcCtD
Etravirine—Connective tissue disorder—Doxorubicin—bone cancer	0.000287	0.00257	CcSEcCtD
Etravirine—Angiopathy—Epirubicin—bone cancer	0.000287	0.00256	CcSEcCtD
Etravirine—Urethral disorder—Doxorubicin—bone cancer	0.000287	0.00256	CcSEcCtD
Etravirine—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000286	0.0106	CbGpPWpGaD
Etravirine—Immune system disorder—Epirubicin—bone cancer	0.000285	0.00255	CcSEcCtD
Etravirine—Mediastinal disorder—Epirubicin—bone cancer	0.000285	0.00254	CcSEcCtD
Etravirine—Vomiting—Cisplatin—bone cancer	0.000278	0.00248	CcSEcCtD
Etravirine—Vision blurred—Methotrexate—bone cancer	0.000277	0.00247	CcSEcCtD
Etravirine—Mental disorder—Epirubicin—bone cancer	0.000277	0.00247	CcSEcCtD
Etravirine—Erythema multiforme—Doxorubicin—bone cancer	0.000277	0.00247	CcSEcCtD
Etravirine—Rash—Cisplatin—bone cancer	0.000276	0.00246	CcSEcCtD
Etravirine—Dermatitis—Cisplatin—bone cancer	0.000275	0.00246	CcSEcCtD
Etravirine—Malnutrition—Epirubicin—bone cancer	0.000275	0.00246	CcSEcCtD
Etravirine—Eye disorder—Doxorubicin—bone cancer	0.000273	0.00244	CcSEcCtD
Etravirine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000273	0.0101	CbGpPWpGaD
Etravirine—Ill-defined disorder—Methotrexate—bone cancer	0.000273	0.00244	CcSEcCtD
Etravirine—Anaemia—Methotrexate—bone cancer	0.000272	0.00243	CcSEcCtD
Etravirine—Cardiac disorder—Doxorubicin—bone cancer	0.000271	0.00242	CcSEcCtD
Etravirine—Flatulence—Epirubicin—bone cancer	0.000271	0.00242	CcSEcCtD
Etravirine—Tension—Epirubicin—bone cancer	0.00027	0.00241	CcSEcCtD
Etravirine—Nervousness—Epirubicin—bone cancer	0.000267	0.00239	CcSEcCtD
Etravirine—Angiopathy—Doxorubicin—bone cancer	0.000265	0.00237	CcSEcCtD
Etravirine—Malaise—Methotrexate—bone cancer	0.000265	0.00237	CcSEcCtD
Etravirine—Immune system disorder—Doxorubicin—bone cancer	0.000264	0.00236	CcSEcCtD
Etravirine—Vertigo—Methotrexate—bone cancer	0.000264	0.00236	CcSEcCtD
Etravirine—Mediastinal disorder—Doxorubicin—bone cancer	0.000264	0.00235	CcSEcCtD
Etravirine—Nausea—Cisplatin—bone cancer	0.00026	0.00232	CcSEcCtD
Etravirine—Vision blurred—Epirubicin—bone cancer	0.000259	0.00232	CcSEcCtD
Etravirine—Mental disorder—Doxorubicin—bone cancer	0.000256	0.00229	CcSEcCtD
Etravirine—Ill-defined disorder—Epirubicin—bone cancer	0.000255	0.00228	CcSEcCtD
Etravirine—Convulsion—Methotrexate—bone cancer	0.000255	0.00228	CcSEcCtD
Etravirine—Malnutrition—Doxorubicin—bone cancer	0.000255	0.00227	CcSEcCtD
Etravirine—Anaemia—Epirubicin—bone cancer	0.000254	0.00227	CcSEcCtD
Etravirine—Flatulence—Doxorubicin—bone cancer	0.000251	0.00224	CcSEcCtD
Etravirine—Tension—Doxorubicin—bone cancer	0.00025	0.00223	CcSEcCtD
Etravirine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000249	0.00222	CcSEcCtD
Etravirine—Malaise—Epirubicin—bone cancer	0.000248	0.00222	CcSEcCtD
Etravirine—Discomfort—Methotrexate—bone cancer	0.000247	0.00221	CcSEcCtD
Etravirine—Nervousness—Doxorubicin—bone cancer	0.000247	0.00221	CcSEcCtD
Etravirine—Vertigo—Epirubicin—bone cancer	0.000247	0.00221	CcSEcCtD
Etravirine—Syncope—Epirubicin—bone cancer	0.000247	0.0022	CcSEcCtD
Etravirine—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000245	0.00905	CbGpPWpGaD
Etravirine—Confusional state—Methotrexate—bone cancer	0.000242	0.00216	CcSEcCtD
Etravirine—Loss of consciousness—Epirubicin—bone cancer	0.000242	0.00216	CcSEcCtD
Etravirine—Vision blurred—Doxorubicin—bone cancer	0.00024	0.00214	CcSEcCtD
Etravirine—Convulsion—Epirubicin—bone cancer	0.000238	0.00213	CcSEcCtD
Etravirine—Infection—Methotrexate—bone cancer	0.000238	0.00213	CcSEcCtD
Etravirine—Hypertension—Epirubicin—bone cancer	0.000238	0.00212	CcSEcCtD
Etravirine—Ill-defined disorder—Doxorubicin—bone cancer	0.000236	0.00211	CcSEcCtD
Etravirine—Nervous system disorder—Methotrexate—bone cancer	0.000235	0.0021	CcSEcCtD
Etravirine—Anaemia—Doxorubicin—bone cancer	0.000235	0.0021	CcSEcCtD
Etravirine—Thrombocytopenia—Methotrexate—bone cancer	0.000235	0.0021	CcSEcCtD
Etravirine—Anxiety—Epirubicin—bone cancer	0.000233	0.00209	CcSEcCtD
Etravirine—Skin disorder—Methotrexate—bone cancer	0.000233	0.00208	CcSEcCtD
Etravirine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000233	0.00208	CcSEcCtD
Etravirine—Hyperhidrosis—Methotrexate—bone cancer	0.000232	0.00207	CcSEcCtD
Etravirine—Discomfort—Epirubicin—bone cancer	0.000231	0.00207	CcSEcCtD
Etravirine—Malaise—Doxorubicin—bone cancer	0.00023	0.00205	CcSEcCtD
Etravirine—Dry mouth—Epirubicin—bone cancer	0.000229	0.00205	CcSEcCtD
Etravirine—Vertigo—Doxorubicin—bone cancer	0.000229	0.00204	CcSEcCtD
Etravirine—Anorexia—Methotrexate—bone cancer	0.000229	0.00204	CcSEcCtD
Etravirine—Syncope—Doxorubicin—bone cancer	0.000228	0.00204	CcSEcCtD
Etravirine—Confusional state—Epirubicin—bone cancer	0.000226	0.00202	CcSEcCtD
Etravirine—Loss of consciousness—Doxorubicin—bone cancer	0.000224	0.002	CcSEcCtD
Etravirine—Infection—Epirubicin—bone cancer	0.000223	0.00199	CcSEcCtD
Etravirine—Shock—Epirubicin—bone cancer	0.000221	0.00197	CcSEcCtD
Etravirine—Convulsion—Doxorubicin—bone cancer	0.000221	0.00197	CcSEcCtD
Etravirine—Nervous system disorder—Epirubicin—bone cancer	0.00022	0.00197	CcSEcCtD
Etravirine—Thrombocytopenia—Epirubicin—bone cancer	0.00022	0.00196	CcSEcCtD
Etravirine—Hypertension—Doxorubicin—bone cancer	0.00022	0.00196	CcSEcCtD
Etravirine—Skin disorder—Epirubicin—bone cancer	0.000218	0.00195	CcSEcCtD
Etravirine—Hyperhidrosis—Epirubicin—bone cancer	0.000217	0.00194	CcSEcCtD
Etravirine—Insomnia—Methotrexate—bone cancer	0.000217	0.00194	CcSEcCtD
Etravirine—Anxiety—Doxorubicin—bone cancer	0.000216	0.00193	CcSEcCtD
Etravirine—Paraesthesia—Methotrexate—bone cancer	0.000215	0.00192	CcSEcCtD
Etravirine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000215	0.00192	CcSEcCtD
Etravirine—Discomfort—Doxorubicin—bone cancer	0.000214	0.00191	CcSEcCtD
Etravirine—Anorexia—Epirubicin—bone cancer	0.000214	0.00191	CcSEcCtD
Etravirine—Somnolence—Methotrexate—bone cancer	0.000213	0.00191	CcSEcCtD
Etravirine—Dry mouth—Doxorubicin—bone cancer	0.000212	0.00189	CcSEcCtD
Etravirine—Confusional state—Doxorubicin—bone cancer	0.00021	0.00187	CcSEcCtD
Etravirine—Decreased appetite—Methotrexate—bone cancer	0.000209	0.00186	CcSEcCtD
Etravirine—Gastrointestinal disorder—Methotrexate—bone cancer	0.000207	0.00185	CcSEcCtD
Etravirine—Fatigue—Methotrexate—bone cancer	0.000207	0.00185	CcSEcCtD
Etravirine—Infection—Doxorubicin—bone cancer	0.000206	0.00184	CcSEcCtD
Etravirine—Pain—Methotrexate—bone cancer	0.000205	0.00183	CcSEcCtD
Etravirine—Shock—Doxorubicin—bone cancer	0.000204	0.00183	CcSEcCtD
Etravirine—Nervous system disorder—Doxorubicin—bone cancer	0.000204	0.00182	CcSEcCtD
Etravirine—Thrombocytopenia—Doxorubicin—bone cancer	0.000203	0.00182	CcSEcCtD
Etravirine—Insomnia—Epirubicin—bone cancer	0.000203	0.00181	CcSEcCtD
Etravirine—Skin disorder—Doxorubicin—bone cancer	0.000202	0.0018	CcSEcCtD
Etravirine—Paraesthesia—Epirubicin—bone cancer	0.000202	0.0018	CcSEcCtD
Etravirine—Hyperhidrosis—Doxorubicin—bone cancer	0.000201	0.00179	CcSEcCtD
Etravirine—Somnolence—Epirubicin—bone cancer	0.0002	0.00178	CcSEcCtD
Etravirine—Anorexia—Doxorubicin—bone cancer	0.000198	0.00177	CcSEcCtD
Etravirine—Feeling abnormal—Methotrexate—bone cancer	0.000198	0.00177	CcSEcCtD
Etravirine—Gastrointestinal pain—Methotrexate—bone cancer	0.000196	0.00175	CcSEcCtD
Etravirine—Decreased appetite—Epirubicin—bone cancer	0.000195	0.00174	CcSEcCtD
Etravirine—Gastrointestinal disorder—Epirubicin—bone cancer	0.000194	0.00173	CcSEcCtD
Etravirine—Fatigue—Epirubicin—bone cancer	0.000194	0.00173	CcSEcCtD
Etravirine—Pain—Epirubicin—bone cancer	0.000192	0.00172	CcSEcCtD
Etravirine—Constipation—Epirubicin—bone cancer	0.000192	0.00172	CcSEcCtD
Etravirine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00019	0.00701	CbGpPWpGaD
Etravirine—Abdominal pain—Methotrexate—bone cancer	0.00019	0.00169	CcSEcCtD
Etravirine—Body temperature increased—Methotrexate—bone cancer	0.00019	0.00169	CcSEcCtD
Etravirine—Insomnia—Doxorubicin—bone cancer	0.000188	0.00168	CcSEcCtD
Etravirine—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000187	0.00692	CbGpPWpGaD
Etravirine—Paraesthesia—Doxorubicin—bone cancer	0.000187	0.00167	CcSEcCtD
Etravirine—Feeling abnormal—Epirubicin—bone cancer	0.000185	0.00165	CcSEcCtD
Etravirine—Somnolence—Doxorubicin—bone cancer	0.000185	0.00165	CcSEcCtD
Etravirine—Gastrointestinal pain—Epirubicin—bone cancer	0.000184	0.00164	CcSEcCtD
Etravirine—Decreased appetite—Doxorubicin—bone cancer	0.000181	0.00161	CcSEcCtD
Etravirine—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000179	0.0016	CcSEcCtD
Etravirine—Fatigue—Doxorubicin—bone cancer	0.000179	0.0016	CcSEcCtD
Etravirine—Pain—Doxorubicin—bone cancer	0.000178	0.00159	CcSEcCtD
Etravirine—Constipation—Doxorubicin—bone cancer	0.000178	0.00159	CcSEcCtD
Etravirine—Abdominal pain—Epirubicin—bone cancer	0.000178	0.00159	CcSEcCtD
Etravirine—Body temperature increased—Epirubicin—bone cancer	0.000178	0.00159	CcSEcCtD
Etravirine—Hypersensitivity—Methotrexate—bone cancer	0.000177	0.00158	CcSEcCtD
Etravirine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000173	0.00639	CbGpPWpGaD
Etravirine—Asthenia—Methotrexate—bone cancer	0.000172	0.00154	CcSEcCtD
Etravirine—Feeling abnormal—Doxorubicin—bone cancer	0.000171	0.00153	CcSEcCtD
Etravirine—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000171	0.00631	CbGpPWpGaD
Etravirine—Gastrointestinal pain—Doxorubicin—bone cancer	0.00017	0.00152	CcSEcCtD
Etravirine—Hypersensitivity—Epirubicin—bone cancer	0.000165	0.00148	CcSEcCtD
Etravirine—Abdominal pain—Doxorubicin—bone cancer	0.000164	0.00147	CcSEcCtD
Etravirine—Body temperature increased—Doxorubicin—bone cancer	0.000164	0.00147	CcSEcCtD
Etravirine—Diarrhoea—Methotrexate—bone cancer	0.000164	0.00147	CcSEcCtD
Etravirine—Asthenia—Epirubicin—bone cancer	0.000161	0.00144	CcSEcCtD
Etravirine—Dizziness—Methotrexate—bone cancer	0.000159	0.00142	CcSEcCtD
Etravirine—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000154	0.00568	CbGpPWpGaD
Etravirine—Diarrhoea—Epirubicin—bone cancer	0.000154	0.00137	CcSEcCtD
Etravirine—Hypersensitivity—Doxorubicin—bone cancer	0.000153	0.00137	CcSEcCtD
Etravirine—Vomiting—Methotrexate—bone cancer	0.000153	0.00136	CcSEcCtD
Etravirine—Rash—Methotrexate—bone cancer	0.000151	0.00135	CcSEcCtD
Etravirine—Dermatitis—Methotrexate—bone cancer	0.000151	0.00135	CcSEcCtD
Etravirine—Headache—Methotrexate—bone cancer	0.00015	0.00134	CcSEcCtD
Etravirine—Asthenia—Doxorubicin—bone cancer	0.000149	0.00133	CcSEcCtD
Etravirine—Dizziness—Epirubicin—bone cancer	0.000148	0.00133	CcSEcCtD
Etravirine—Vomiting—Epirubicin—bone cancer	0.000143	0.00128	CcSEcCtD
Etravirine—Nausea—Methotrexate—bone cancer	0.000143	0.00127	CcSEcCtD
Etravirine—Diarrhoea—Doxorubicin—bone cancer	0.000142	0.00127	CcSEcCtD
Etravirine—Rash—Epirubicin—bone cancer	0.000142	0.00126	CcSEcCtD
Etravirine—Dermatitis—Epirubicin—bone cancer	0.000141	0.00126	CcSEcCtD
Etravirine—Headache—Epirubicin—bone cancer	0.000141	0.00126	CcSEcCtD
Etravirine—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00014	0.00518	CbGpPWpGaD
Etravirine—Dizziness—Doxorubicin—bone cancer	0.000137	0.00123	CcSEcCtD
Etravirine—ABCB4—Metabolism—ENO2—bone cancer	0.000135	0.00498	CbGpPWpGaD
Etravirine—Nausea—Epirubicin—bone cancer	0.000133	0.00119	CcSEcCtD
Etravirine—Vomiting—Doxorubicin—bone cancer	0.000132	0.00118	CcSEcCtD
Etravirine—Rash—Doxorubicin—bone cancer	0.000131	0.00117	CcSEcCtD
Etravirine—Dermatitis—Doxorubicin—bone cancer	0.000131	0.00117	CcSEcCtD
Etravirine—Headache—Doxorubicin—bone cancer	0.00013	0.00116	CcSEcCtD
Etravirine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000127	0.00469	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—DHFR—bone cancer	0.000125	0.00462	CbGpPWpGaD
Etravirine—Nausea—Doxorubicin—bone cancer	0.000123	0.0011	CcSEcCtD
Etravirine—ABCB4—Metabolism—GNA11—bone cancer	0.000117	0.00432	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—CYP3A4—bone cancer	0.000106	0.00391	CbGpPWpGaD
Etravirine—ABCB4—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000106	0.0039	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000104	0.00384	CbGpPWpGaD
Etravirine—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	9.74e-05	0.00359	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—GSTP1—bone cancer	9.08e-05	0.00335	CbGpPWpGaD
Etravirine—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	8.88e-05	0.00328	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	8.86e-05	0.00327	CbGpPWpGaD
Etravirine—CYP2C19—Biological oxidations—CYP3A4—bone cancer	8.18e-05	0.00302	CbGpPWpGaD
Etravirine—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	8.07e-05	0.00298	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	8.06e-05	0.00297	CbGpPWpGaD
Etravirine—CYP2C9—Biological oxidations—CYP3A4—bone cancer	7.46e-05	0.00275	CbGpPWpGaD
Etravirine—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	7.36e-05	0.00271	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	7.34e-05	0.00271	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	7.24e-05	0.00267	CbGpPWpGaD
Etravirine—CYP2C19—Biological oxidations—GSTP1—bone cancer	7e-05	0.00258	CbGpPWpGaD
Etravirine—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	6.9e-05	0.00255	CbGpPWpGaD
Etravirine—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	6.86e-05	0.00253	CbGpPWpGaD
Etravirine—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	6.49e-05	0.0024	CbGpPWpGaD
Etravirine—CYP2C9—Biological oxidations—GSTP1—bone cancer	6.38e-05	0.00235	CbGpPWpGaD
Etravirine—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	6.29e-05	0.00232	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	6.14e-05	0.00226	CbGpPWpGaD
Etravirine—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	6.12e-05	0.00226	CbGpPWpGaD
Etravirine—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	5.28e-05	0.00195	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—NDUFA12—bone cancer	4.9e-05	0.00181	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—NDUFA12—bone cancer	4.79e-05	0.00177	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—PTGS2—bone cancer	4.7e-05	0.00173	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	4.55e-05	0.00168	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—NDUFA12—bone cancer	4.47e-05	0.00165	CbGpPWpGaD
Etravirine—CYP3A4—Biological oxidations—GSTP1—bone cancer	4.21e-05	0.00155	CbGpPWpGaD
Etravirine—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	4.15e-05	0.00153	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—NT5C3A—bone cancer	4.06e-05	0.0015	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—NT5C3A—bone cancer	3.97e-05	0.00146	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—NT5C3A—bone cancer	3.7e-05	0.00137	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	3.37e-05	0.00124	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	3.25e-05	0.0012	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—NDUFA12—bone cancer	2.95e-05	0.00109	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	2.93e-05	0.00108	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—NT5C3A—bone cancer	2.44e-05	0.000901	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.31e-05	0.000851	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.94e-05	0.000714	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—ENO2—bone cancer	1.78e-05	0.000657	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—ENO2—bone cancer	1.74e-05	0.000641	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—DHFR—bone cancer	1.65e-05	0.000609	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—ENO2—bone cancer	1.62e-05	0.000599	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—DHFR—bone cancer	1.61e-05	0.000595	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—GNA11—bone cancer	1.54e-05	0.000569	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—GNA11—bone cancer	1.51e-05	0.000556	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—DHFR—bone cancer	1.51e-05	0.000555	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—GNA11—bone cancer	1.41e-05	0.000519	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—CYP3A4—bone cancer	1.4e-05	0.000516	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.39e-05	0.000513	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—CYP3A4—bone cancer	1.37e-05	0.000504	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—CYP3A4—bone cancer	1.28e-05	0.000471	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.27e-05	0.000468	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—GSTP1—bone cancer	1.2e-05	0.000441	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—GSTP1—bone cancer	1.17e-05	0.000431	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—GSTP1—bone cancer	1.09e-05	0.000402	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—ENO2—bone cancer	1.07e-05	0.000395	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—DHFR—bone cancer	9.93e-06	0.000366	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—GNA11—bone cancer	9.28e-06	0.000342	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—GSTP1—bone cancer	7.2e-06	0.000265	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—PTGS2—bone cancer	6.2e-06	0.000229	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—PTGS2—bone cancer	6.05e-06	0.000223	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—PTGS2—bone cancer	5.65e-06	0.000209	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—PTGS2—bone cancer	3.73e-06	0.000138	CbGpPWpGaD
